The SURMOUNT-1 trial (tirzepatide, published in NEJM 2022) demonstrated that participants with obesity or overweight without diabetes who received tirzepatide experienced weight reductions of 16.0% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results